S. Mubareka

This study shows that paridiprubart, a TLR4 inhibitor, suppresses NF-κB activation by multiple pathogens including SARS-CoV-2 and bacterial agents.

This study develops a multimeric antibody platform (Multabody) that enhances neutralization potency and breadth against SARS-CoV-2 and its variants through avidity and multi-specificity.

This study conducted SARS-CoV-2 surveillance in urban wildlife in Ontario and Quebec, Canada, finding no evidence of viral RNA or neutralizing antibodies in tested samples.

The paper identifies a highly divergent SARS-CoV-2 lineage in white-tailed deer with evidence of deer-to-human transmission.

This study identifies a MMP2/9-dependent entry pathway for SARS-CoV-2 and variants, showing differential usage and reduced activity in Omicron.

The paper characterizes Delta SARS-CoV-2 infection in white-tailed deer using genomic and transcriptomic analyses, identifying mutations and host immune responses.

This study tracks SARS-CoV-2-specific T cell cytokine responses over one year, finding persistent multi-cytokine production with greater immunity linked to disease severity.

The paper assesses neutralizing antibody responses of convalescent and vaccinated sera against SARS-CoV-2 ancestral, beta, delta, and omicron variants.

This study investigates how exposure route, sex, and age affect SARS-CoV-2 pathogenesis in golden Syrian hamsters, finding significant differences in disease outcomes.

This paper evaluates a SARS-CoV-2 mRNA vaccine, PTX-COVID19-B, showing it is safe, effective, and induces strong immune responses in mice and hamsters, with ongoing human clinical trials.

This study shows SARS-CoV-2 and related coronaviruses induce processing body disassembly, with SARS-CoV-2's N protein uniquely causing this effect, leading to increased proinflammatory cytokine production.

The paper introduces a protein-based assay to detect neutralizing antibodies against SARS-CoV-2, showing it correlates with traditional viral neutralization tests.

This study shows SARS-CoV-2 infection induces a mild type I IFN response in vitro and in moderate COVID-19 cases, and cannot inhibit exogenous IFN induction.

The paper isolates SARS-CoV-2 from two patients, sequences the virus, and tests its infectivity in human immune cells, finding that PBMCs are not permissive to infection.